Bimatoprost · Durysta, Latisse

What is Bimatoprost?

Bimatoprost is a synthetic prostaglandin analog with ocular hypotensive activity. It is believed to lower intraocular pressure by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral routes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Durysta, Latisse, Lumigan, Zolymbus, AGN-192024

Drug type

Small molecule

Mechanism

Modulator

Pathways

aqueous humor outflow through trabecular meshwork and uveoscleral routes

Therapy area

Ophthalmology

Developer

Abbvie

In trials of

AMRX

FDA status

Approved as Durysta, Latisse, Lumigan (March 16, 2001), NDA021275 · FDA label

UNII

QXS94885MZ

✅ FDA-approved uses

• Open-angle glaucoma or ocular hypertension (Zolymbus)
• Open angle glaucoma or ocular hypertension (Durysta)
• Hypotrichosis of the eyelashes (Latisse)
• Open angle glaucoma or ocular hypertension (Lumigan)

From the indications section of the FDA label (version of Feb 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glaucoma, Open-AngleOcular HypertensionOpen-angle Glaucoma

Sources

• FDA label (DailyMed)
• FDA label Zolymbus (2026-02-25), indications
• FDA label Durysta (2024-10-16), indications
• FDA label Latisse (2024-07-01), indications
• FDA label Lumigan (2024-06-22), indications
• ClinicalTrials.gov NCT05401357
• ClinicalTrials.gov NCT05401357
• ClinicalTrials.gov NCT06267274

Updated Oct 11, 2026.